https://www.selleckchem.com/products/ms-275.html
Gonadotropin-releasing hormone analogs are the treatment of choice for central precocious puberty (CPP). This study characterizes patients treated with histrelin implant or leuprolide injection. A US claims database was used to identify patients aged ≤20 years with ≥1 histrelin or leuprolide claim (index treatment) between April 2010 and November 2017 and continuous enrollment ≥3 months before and ≥12 months after the index treatment date. Overall, 4,217 patients (histrelin, n=1,001; leuprolide, n=3,216) were identified. The percentage o
Like
Comment
Share
